FDA’s fast public posture unsettles regulation

The FDA is moving in two speeds at once. Publicly, it is fast, loud, and everywhere — rolling out AI tools, announcing pilot inspections, and using the newsroom like a running product feed. But the legal machinery that actually tells companies what the rules are is still moving the old way. That gap is now starting to matter, especially in dietary supplements, where firms are getting policy signals without the certainty of a finished rule. ### What changed this week? The agency put out a burst of announcements in early May. On May 6, it said it had upgraded its internal AI system to Elsa 4.0 and consolidated more than 40 data sources. The same day, it announced a pilot for one-day inspectional assessments. The tone was clear — faster oversight, faster review, more visible action. (fda.gov) ### Why does that feel different? Because this is not just normal FDA housekeeping. The agency is presenting itself almost like a live operator — constantly signaling direction before the slower parts of regulation catch up. Martin Makary’s earlier AI rollout message made that explicit. He said agency-wide use of generative AI should be in place by June 30, 2025, framing speed itself as the priority. (fda.gov) ### Where does supplements law come in? Supplements are where the mismatch is easiest to see. The core legal framework is still old-school DSHEA territory, and some of the actual regulations on the books date back to the late 1990s. For new dietary ingredients, manufacturers still face the formal 75-day premarket notification process under 21 CFR Part 190. That is real law, not a press release. (ecfr.gov) ### So what is the specific supplement fight? It is about the DSHEA disclaimer on labels. In December 2025, FDA told industry it would use enforcement discretion on where that disclaimer appears, signaling flexibility on the long-disputed requirement that claims and disclaimers be linked across label panels. But that was a letter, not a completed rule. On May 6, the Council for Responsible Nutrition filed a(ecfr.gov)direct final rule. (fda.gov) ### Why isn’t the letter enough? Because enforcement discretion is basically the agency saying, “We are not planning to push this issue right now.” That helps, but it is not the same as changing the rule itself. Companies still have to think about litigation, state-law claims, and the chance that a future FDA leadership team could read the same text differently. CRN’s petition says that uncertainty is already creating legal risk despite decades of accepted market practice. (crnusa.org) ### What does vaccine-study controversy have to do with this? It shows the same broader pattern — fast public posture, murkier process underneath. Reports this week said FDA leaders blocked or delayed publication of internal studies that found no major safety signals for COVID-19 and shingles vaccines. HHS said the issue was not the data itself but conclusions th(crnusa.org)blic. (pharmacytimes.com) ### Is the AI push part of the same story? Yes — not because AI is bad, but because it reinforces the sense that the agency wants visible speed. Elsa’s pitch is that review work that once took days can take minutes. One-day inspections are pitched the same way — more targeted, less cumbersome, more scalable. That may improve operations. But it also trains industry to read announcements as policy signals even when formal standards have not changed. (fda.gov) ### Who feels this first? Supplement makers, pharmacists, and consumers. Manufacturers need to know what will survive a lawsuit. Pharmacists need to explain what FDA process fights do and do not mean for safety. Consumers just see mixed signals — strong public messaging, but less clarity on what is actually binding. (pharmacytime([fda.gov)? The FDA is acting like a faster agency before it has fully become a faster rulemaker. That can make oversight feel more responsive. But until the formal rules catch up, the loudest signal is not always the clearest one.